Recent advances in application of pharmacogenomics for biotherapeutics

AAPS Journal

Volumn 18, Issue 3, 2016, Pages 605-611

  Mahajan, Pramod B ^a  

^a DRAKE UNIVERSITY   (United States)

Author keywords

Biologicals; Biotherapeutics; Genetic variability; Pharmacogenomics

Indexed keywords

ADALIMUMAB; BELIMUMAB; BEVACIZUMAB; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; BRENTUXIMAB VEDOTIN; CETUXIMAB; DENILEUKIN DIFTITOX; ETANERCEPT; HUMAN INSULIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INSULIN GLARGINE; OBINUTUZUMAB; OFATUMUMAB; PANITUMUMAB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGLOTICASE; PERTUZUMAB; RASBURICASE; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; RECOMBINANT PROTEIN;

BIOLOGICAL THERAPY; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG METABOLISM; DRUG SPECIFICITY; DRUG TARGETING; GOUT; HEPATITIS C; HUMAN; IMMUNOGENICITY; NONHODGKIN LYMPHOMA; PHARMACOGENOMICS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; ANIMAL; METABOLISM; PHARMACEUTICS; PHARMACOGENETICS; PROCEDURES; TRENDS;

ANIMALS; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; BIOPHARMACEUTICS; HUMANS; PHARMACOGENETICS; RECOMBINANT PROTEINS;

EID: 85007415352     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-016-9903-4     Document Type: Review

References (86)

1. The US FDA. http://www.fda.gov/drugs/informationondrugs/ucm079436.htm#ther_biological Accessed 15 Sept 2015.
2. Dimitrov DS. Therapeutic proteins. Therapeutic proteins: methods and protocols. In: Voynov V, Caravella JA, editors. Methods in molecular biology, vol. 899. New York: Humana Press; 2012. p. 1–26.
3. Kinch MS. An overview of FDA-approved biologics medicines. Drug Di scov Today. 2015; 20(4): 393–8. doi: 10.1016/j.drudis.2014.09.003.
4. Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res. 2011;317(9):1261–69.
5. Kling J. Fresh from the biotech pipeline—2013. Nat Biotechnol. 2014;32(2):121–4. doi:10.1038/nbt.2811.
6. Morrison C. Fresh from the biotech pipeline—2014. Nat Biotechnol. 2015;33(2):125–8. doi:10.1038/nbt.3136.
7. Rader RA. (Re)defining biopharmaceutical. Nat Biotechnol. 2008;26(7):743–51. doi:10.1038/nbt0708-743.
8. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21–39. Review.
9. White Junod, S. (2007) Celebrating a milestone: FDA’s approval of first genetically-engineered product: http://www.fda.gov/aboutfda/whatwedo/history/productregulation/selectionsfromfdliupdateseriesonfdahistory/ucm081964.htm Accessed 29 Sept 2015.
10. Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol. 2014;32(10):992–1000. doi:10.1038/nbt.3040.
11. C & E News Supplement Sept 2014 http://cen.acs.org/content/dam/cen/supplements/CEN-supplement092014.pdf.
12. Philippidis A. (2015) The top 25 best-selling drugs of 2014. http://www.genengnews.com/insight-and-intelligence/the-top-25-best-selling-drugs-of-2014/77900383/#gsaccess. Accessed 15 Sept 2015.
13. Bui LA et al. Key considerations in the preclinical development of biosimilars. Drug Discov Today. 2015;20 Suppl 1:3–15. doi:10.1016/j.drudis.2015.03.011.
14. Tsuruta LR et al. Biosimilars advancements: moving on to the future. Biotechnol Prog. 2015;31(5):1139–49. doi:10.1002/ btpr.2066.
15. Kumar R, Singh J. Biosimilar drugs: current status. Int J Appl Basic Med Res. 2014;4(2):63–6. doi:10.4103/2229-516X.136774.
16. Müller R et al. The advent of biosimilars: challenges and risks. Swiss Med Wkly. 2014;144:w13980. doi:10.4414/smw.2014.13980.
17. Wadhwa M et al. Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility. Biologicals. 2015;43(5):298–306. doi:10.1016/j.biologicals.2015.06.004.
18. Rup B et al. ABIRISK consortium. Standardizing terms definitions and concepts for describing and interpreting unwanted immunogeni-city of biopharmaceuticals: recommendations of the innovative medicines initiative ABIRISK consortium. Clin Exp Immunol. 2015;181(3):385–400. doi:10.1111/cei.12652.
19. Yin L et al. Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cell Immunol. 2015;295(2):118–26. doi:10.1016/ j.cellimm.2015.03.002.
20. Kloks C et al. A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective. J Immunol Methods. 2015;417:1–9. doi:10.1016/ j.jim.2015.01.003.
21. Bendtzen K. Immunogenicity of anti-TNF-α biotherapies: I. Individualized medicine based on immunopharmacological evidence. Fr ont I mmunol. 2015; 6: 152. doi: 10.3389/fimmu.2015.00152.
22. Deehan M et al. Managing unwanted immunogenicity of biologicals. Autoimmun Rev. 2015;14(7):569–74. doi:10.1016/j.autrev.2015.02.007.
23. Garrod A. The incidence of alkaptonuria: a study in chemical individuality. Lancet. 1902;2:1616–20.
24. Dern RJ et al. The hemolytic effect of primaquine. I. The localization of the drug-induced hemolytic defect in primaquine-sensitive individuals. J Lab Clin Med. 1954;43(2):303–9.
25. Buetler E. The hemolytic effects of primaquine and related compounds: a review. Blood. 1959;14(2):103–39.
26. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960;2(5197):485–91.
27. Whirl-Carrillo M. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–7. Also a Web resource: https://www.pharmgkb.org/page/citingPharmgkb.
28. The US FDA. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
29. The European Medicines Agency. http://www.ema.europa.eu/ema/.
30. The Pharmaceuticals and Medical Devices Agency, Japan. http://www.pmda.go.jp/english/.
31. The Health Canada/Sante’ Canada http://www.hc-sc.gc.ca/index-eng.php.
32. Dubovsky SL. The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression. Expert Opin Drug Metab Toxicol. 2015;11(3):369–79. doi:10.1517/17425255.2015.998996.
33. Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry. 2014;59(2):76–88.
34. Pandey AV, Sproll P. Pharmacogenomics of human P450 oxidoreductase. Front Pharmacol. 2014;5:103. doi:10.3389/fphar.2014.00103.
35. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab. 2014;15(2):218–32.
36. Yiannakopoulou EC. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications. Pharmacogenomics J. 2013;13(2):105–9. doi:10.1038/tpj.2012.42.
37. Si m SC, Kac evska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013;13(1):1–11. doi:10.1038/tpj.2012.45.
38. Nies AT et al. Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Adv Cancer Res. 2015;125:217– 43. doi:10.1016/bs.acr.2014.10.007.
39. Lima A et al. Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers. Pharmacogenomics. 2014;15(12):1611–35. doi:10.2217/pgs.14.116.
40. Dietrich CG, Geier A. Effect of drug transporter pharmacogenetics on cholestasis. Expert Opin Drug Metab Toxicol. 2014;10(11):1533–51. doi:10.1517/17425255.2014.963553.
41. Sissung TM et al. Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol Biol. 2014;1175:91– 120. doi:10.1007/978-1-4939-0956-8_6.
42. Evrard A, Mbatchi L. Genetic polymorphisms of drug metabolizing enzymes and transporters: the long way from bench to bedside. Curr Top Med Chem. 2012;12(15):1720–9.
43. Sissung TM et al. Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharma-cotherapy. Discov Med. 2012;13(68):19–34.
44. Silverton L, Dean M, Moitra K. Variation and evolution of the ABC transporter genes ABCB1, ABCC1, ABCG2, ABCG5 and ABCG8: implication for pharmacogenetics and disease. Drug Metabol Drug Interact. 2011;26(4):169–79. doi:10.1515/DMDI.2011.027.
45. Tang H, McGowan OO, Reynolds GP. Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action. Pharmacogenomics. 2014;15(12):1599–609. doi:10.2217/pgs.14.111.
46. Fontana V, Luizon MR, Sandrim VC. An update on the pharmacogenetics of treating hypertension. J Hum Hypertens. 2015;29(5):283–91. doi:10.1038/jhh.2014.76.
47. Levy F. Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder. Pharmgenomics Pers Med. 2014;7:349–56. doi:10.2147/PGPM.S52844.
48. Femminella GD et al. Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. Pharmgenomics Pers Med. 2014;7:267–73. doi:10.2147/PGPM.S49799.
49. Thompson MD et al. Pharmacogenetics of the G protein-coupled receptors. Methods Mol Biol. 2014;1175:189–242. doi:10.1007/978-1-4939-0956-8_9.
50. Thompson MD et al. G protein-coupled receptor accessory proteins and signaling: pharmacogenomic insights. Methods Mol Biol. 2014;1175:121–52. doi:10.1007/978-1-4939-0956-8_7.
51. Ahles A, Engelhardt S. Polymorphic variants of adrenoceptors: pharmacology, physiology, and role in disease. Pharmacol Rev. 2014;66(3):598–637. doi:10.1124/pr.113.008219.
52. Ortega VE. Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management. Clin Genet. 2014;86(1):12–20. doi:10.1111/cge.12377.
53. Knapman A, Connor M. Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1). Br J Pharmacol. 2015;172(2):349–63. doi:10.1111/bph.12644.
54. Relling MV et al. Clinical pharmacogenetics implementation consortium. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD defici ency genot ype. Clin Pharmacol Ther. 2014;96(2):169–74. doi:10.1038/clpt.2014.97.
55. Muir AJ et al. Clinical pharmacogenetics implementation consortium (CPIC). clinical pharmacogenetics implementation consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther. 2014;95(2):141–6. doi:10.1038/clpt.2013.203.
56. Krejsa C, Rogge M, Sadee W. Protein therapeutics: new applications for pharmacogenetics. Nat Rev Drug Discov. 2006;5(6):507–21.
57. Lacaná E et al. The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther. 2007;82(4):466–71.
58. Yanover C et al. Pharmacogenetics and the immunogenicity of protein therapeutics. Nat Biotechnol. 2011;29(10):870–3. doi:10.1038/nbt.2002.
59. Posteraro B et al. The link between genetic variation and variability in vaccine responses: systematic review and meta-anal yses. Vaccine. 2014; 32(15): 1661–9. doi: 10. 1016/j.vaccine.2014.01.057.
60. Pandey GS, Sauna ZE. Pharmacogenetics and the immunogenicity of protein therapeutics. J Interferon Cytokine Res. 2014;34(12):931–7.
61. Burke W, Korngiebel DM. Closing the gap between knowledge and clinical application: challenges for genomic translation. PLoS Genet. 2015;11(2):e1004978. doi:10.1371/journal.pgen.1004978.
62. Carlson RJ et al. Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress? Cytokine Growth Factor Rev. 2015;26(2):249– 61. doi:10.1016/j.cytogfr.2014.10.008.
63. Pellegrino P et al. The first steps towards the era of personalised vaccinology: predicting adverse reactions. Pharmacogenomics J. 2015;15(3):284–7. doi:10.1038/tpj.2014.57.
64. Pavlos R et al. T cell-mediated hypersensitivity reactions to drugs. Annu Rev Med. 2015;66:439–54.
65. Singh SK et al. Determinants of immunogenic response to protein therapeutics. Biologicals. 2012;40(5):364–8. doi:10.1016/ j.biologicals.2012.06.001.
66. De Barros MF et al. Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil. Haemophilia. 2012;18(3):e236–40. doi:10.1111/j.1365-2516.2011.02604.x.
67. Pandey GS et al. PATH (personalized alternative therapies for hemophilia) study investigators. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia a. Nat Med. 2013;19(10):1318–24. doi:10.1038/nm.3270.
68. Pandey GS et al. Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment. PLoS Comput Biol. 2013;9(5):e1003066. doi:10.1371/journal.pcbi.1003066.
69. Pashov AD et al. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia. 2014;20(2):176–84. doi:10.1111/hae.12276.
70. Lochan A et al. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014;20(5):687–92. doi:10.1111/hae.12436.
71. Pellegrino P et al. The role of toll-like receptor 4 polymorphisms in vaccine immune response. Pharmacogenomics J. 2015. doi:10.1038/tpj.2015.21.
72. Mentzer AJ et al. Searching for the human genetic factors standing in the way of universally effective vaccines. Philos Trans R Soc Lond B Biol Sci. 2015;370(1671):20140341. doi:10.1098/rstb.2014.0341.
73. Li ZK et al. The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine. 2013; 31(40): 4355–61. doi: 10.1016/j.vaccine.2013.06.108.
74. Yan K et al. Genetic effects have a dominant role on poor responses to infant vaccination to hepatitis B virus. J Hum Genet. 2013;58(5):293–7. doi:10.1038/jhg.2013.18.
75. Lin YJ et al. Effects of cytokine and cytokine receptor gene variation on high anti-HB titers: following up on Taiwan’s neonatal hepatitis B immunization program. Clin Chim Acta. 2012; 413(15–16): 1194–8. doi: 10.1016/j.cca.2012.03.004.
76. Hennig BJ, Hall AJ. Host genetic factors in hepatitis B infection, liver cancer and vaccination response: a review with a focus on Africa. Sci Total Environ. 2012;423:202–9. doi:10.1016/j.scitotenv.2010.09.036.
77. Kamal SM. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med. 2014;6:61–77. doi:10.2147/HMER.S41127.
78. Zhang L, Gwinn M, Hu DJ. Viral hepatitis C gets personal—the value of human genomics to public health. Public Health Genomics. 2013;16(4):192–7. doi:10.1159/000352014.
79. Ansaldi F et al. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014;20(29):9633–52. doi:10.3748/wjg.v20.i29.9633.
80. Dhiman N et al. SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics. 2010;62(4):197–210.
81. Yucesoy B et al. Influence of cytokine gene variations on immunization to childhood vacci nes. Vaccine. 2009;27(50):6991–7.
82. Yucesoy B et al. Genetic variants within the MHC region are associated with immune responsiveness to childhood vaccinations. Vaccine. 2013; 31(46): 5381– 91. doi: 10.1016/j.vaccine.2013.09.026.
83. Haralambieva IH et al. Variability in humoral immunity to measles vaccine: new developments. Trends Mol Med. 2015; S1471–S4914(15): 00195–1. doi:10.1016/j.molmed.2015.10.005.
84. Ouattara A et al. Polymorphisms in the K13-propeller gene in artemisinin-susceptible plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara Mali. Am J Trop Med Hyg. 2015;92(6):1202–6. doi:10.4269/ajtmh.14-0605.
85. Bender E. Big data in biomedicine. Nature. 2015;527(7576):S1. doi:10.1038/527S1a.
86. Eisenstein M. Big data: the power of petabytes. Nature. 2015;527(7576):S2–4. doi:10.1038/527S2a.